Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Shareholders' Equity (Tables)

v3.26.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2025
Shareholders' Equity [Abstract]  
Schedule of Information Regarding Outstanding Warrants to Purchase Shares

The following table summarizes information regarding outstanding warrants to purchase the Company’s ordinary shares as of December 31, 2025:

 

Issuance date   Number of
outstanding
Warrants
    Exercise
price per
warrant
 
             
December 2021     3,500     $ 200.0  
January 2023 agent     9,545     $ 68.75  
November 2023     243,377     $ 17.50  
November 2023 agent     13,746     $ 19.13  
August 2024     571,429     $ 22.50  
August 2024 agent     20,000     $ 21.90  
April 2025     17,500     $ 15.0  
July 2025     1,666,667     $ 4.67  
July 2025     58,333     $ 7.50  
      2,604,097          
Schedule of Company's Option Activity

The following table summarizes Company’s option activity during the year ended December 31, 2025: 

 

    Number of
options
    Weighted
average
exercise
price
    Weighted
average
remaining
contractual
terms
(in years)
    Aggregate
intrinsic
value
 
                         
Outstanding at December 31, 2024     41,610       90       7.1       -  
Grants     8,000       16.01       10       -  
Forfeited/expired     (77 )     -       -            -  
                                 
Outstanding at December 31, 2025     49,533       87.31       6.6       -  
                                 
Vested and expected to vest at December 31, 2025     49,533       87.31       6.6       -  
                                 
Exercisable at December 31, 2025     25,497       143.98       5.7       -  
Schedule of Fair value of Company’s Share Options Granted

The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions:

 

Description   2025   2024   2023
             
Risk-free interest rate   4.04%-4.21%   4.64%-5.09%   3.95%-3.96%
Expected volatility   79.56%-79.82%   83.40%-83.94%   84.30%-84.76%
Dividend yield   0%   0%   0%
Contractual life (in years)   10   9.75-10   10
Early Exercise Multiple (Suboptimal Factor)   2.5   2.5   2.5
Schedule of Expenses Recognized Financial Statements Expenses recognized in the financial statements:

 

    Year ended December 31,  
    2025     2024     2023  
                   
Research and development   $ 57     $ 75     $ 83  
General and administrative (*)     283       287       178  
      340       362       261  

 

(*) Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.